New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Bristol Myers Squibb Company

BMY

Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue
+6.93%
EPS
−2.78%
Free cash flow
−36.0%
Total debt
−12.5%

Quarter to September 2026, against a year earlier

59.42 1.08 +1.85%
Market cap
$119.3B
P/E
12.9×
Fwd P/E FY26e
12.0×
Dividend yield
4.32%
F-score
8/9
ROIC
13.2%
Net debt / EBITDA
2.6×
Payout ratio
0.6×

Bristol Myers Squibb Company 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 11:16 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2026: 11 added · 7 removed · 38 modified; 17 with only figures updated; 1 moved without change

  1. Modified · EXECUTIVE SUMMARY

    In 2026, we made meaningful progress advancing have achieved multiple regulatory approvals across our pipelineportfolio, highlighted byincluding: (i) FDA acceptance approval of our NDA for first CELMoD, Zenbexus (iberdomide), in RRMMcombination with a PDUFA date daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of August 17, 2026adult patients with MM who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent in the U.S.; (ii) FDA acceptance approval of our NDA Camzyos for mezigdomide pediatric patients with symptomatic oHCM in RRMM with a PDUFA date the U.S.; (iii) approval of Sotyktu for the treatment of May 13, 2027adults with active PsA in the U.S. and EU; and (iiiiv) positive interim approval of Opdivo for cHL in the U.S. and EU. We have also made meaningful progress advancing our pipeline, highlighted by: (i) topline Phase IIIII results from the ROSETTA Lung-02 ALOFT-IPF study of pumitamigadmilparant in patientsadults with previously untreated advanced NSCLCIPF, which met its primary endpoint at the 60 mg dose; (ivii) positive topline interim results from two Phase III studies conducted in China for iza-bren results from the ACTION-1 study of RYZ101 in heavily pretreated, unresectable locally advanced or metastatic TNBC and recurrent or metastatic ESCCpatients with SSTR+ GEP-NETs who have progressed following Lu177-based therapy; and (viii) FDA acceptance of our sNDANDA for Camzyosmezigdomide in adolescentsRRMM with symptomatic oHCM with a PDUFA date of September 30May 13, 2026. Additionally, Sotyktu was approved in 2027; (iv) positive interim Phase II results from the U.S. and EU for ROSETTA Lung-02 study of pumitamig in patients with previously untreated advanced NSCLC; (v) positive topline Phase II results from the treatment registrational QUINTESSENTIAL study of adults arlo-cel in adult patients with active PsA quadruple-class exposed RRMM; and Opdivo was approved (vi) positive interim results from two Phase III studies conducted in the U.S. China for iza-bren in heavily pretreated, unresectable locally advanced or metastatic TNBC and EU for cHLrecurrent or metastatic ESCC.